Business
INVO Fertility Announces a 1:5 Reverse Stock Split Effective Pre-Market Opening on March 27, 2026
SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (“INVO”) (NASDAQ: IVF), a healthcare company focused on the fertility market,
About this update from Invo Fertility, Inc.
[{"type":"text","content":"SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (“INVO”) (NASDAQ: IVF), a healthcare company focused on the fertility market, announced today that it will effect a 1-for-5 reverse split of its issued and outstanding and of its authorized common stock effective as of 12:01 a.m. Eastern Time on March 27, 2026. Commencing with the opening of trading on The Nasdaq Capital Market on March 27, 2026, the Company’s common stock will trade on a post-split basis under the same trading symbol, “IVF”. As a result of the reverse stock split, the CUSIP number for the Company’s common stock will be 44984F880. As a result of the reverse stock split, every 5 shares of issued and outstanding common stock will be exchanged for 1 share of common stock. Registered holders of record who would otherwise hold a fractional share will be rounded up to the next whole share. Beneficial holders holding shares in street name through a broker or nominee who would otherwise be entitled to receive a fractional share will receive a cash payment for such fractional interest, the amount of which will be determined and administered by the applicable broker or nominee in accordance with their standard procedures. Immediately after the reverse stock split becomes effective, the company will have approximately 1,615,419 shares of common stock issued and outstanding. In addition, a proportionate adjustment will be made to the company’s authorized shares of common stock such that the Company shall have 50,000,000 shares of authorized common stock after the effective time of the reverse stock split. About INVO Fertility We are a healthcare services fertility company dedicated to expanding assisted reproductive technology (“ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring and operating fertility clinics, including “INVO Centers” dedicated primarily to offering the intravaginal culture (“IVC”) procedure enabled by our INVOcell® medical device (“INVOcell”) and US-based, profitable in vitro fertilization (“IVF”) clinics. We have four fertility clinics in the United States. We also continue to engage in the sale and distribution of our INVOcell technology solution into third-party owned and operated fertility clinics. The INVOcell is a proprietary and revolutionary medical device, and the first to allo...